RU2746188C2 - Ингибиторы ионного канала, фармацевтические составы и применение - Google Patents

Ингибиторы ионного канала, фармацевтические составы и применение Download PDF

Info

Publication number
RU2746188C2
RU2746188C2 RU2018121288A RU2018121288A RU2746188C2 RU 2746188 C2 RU2746188 C2 RU 2746188C2 RU 2018121288 A RU2018121288 A RU 2018121288A RU 2018121288 A RU2018121288 A RU 2018121288A RU 2746188 C2 RU2746188 C2 RU 2746188C2
Authority
RU
Russia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
azaspiro
exemplary embodiment
Prior art date
Application number
RU2018121288A
Other languages
English (en)
Russian (ru)
Other versions
RU2018121288A (ru
RU2018121288A3 (enExample
Inventor
Синьминь СЕ
Франк Кайзер
Original Assignee
Афаски, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Афаски, Инк. filed Critical Афаски, Инк.
Publication of RU2018121288A publication Critical patent/RU2018121288A/ru
Publication of RU2018121288A3 publication Critical patent/RU2018121288A3/ru
Application granted granted Critical
Publication of RU2746188C2 publication Critical patent/RU2746188C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2018121288A 2015-11-12 2016-11-14 Ингибиторы ионного канала, фармацевтические составы и применение RU2746188C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562254564P 2015-11-12 2015-11-12
US62/254,564 2015-11-12
PCT/US2016/061918 WO2017083867A1 (en) 2015-11-12 2016-11-14 Ion channel inhibitory compounds, pharmaceutical formulations and uses

Publications (3)

Publication Number Publication Date
RU2018121288A RU2018121288A (ru) 2019-12-16
RU2018121288A3 RU2018121288A3 (enExample) 2020-03-27
RU2746188C2 true RU2746188C2 (ru) 2021-04-08

Family

ID=58696184

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018121288A RU2746188C2 (ru) 2015-11-12 2016-11-14 Ингибиторы ионного канала, фармацевтические составы и применение

Country Status (15)

Country Link
US (1) US10562857B2 (enExample)
EP (1) EP3340988B1 (enExample)
JP (1) JP6790094B2 (enExample)
KR (1) KR102217524B1 (enExample)
CN (1) CN108289886B (enExample)
AU (1) AU2016353446B2 (enExample)
BR (1) BR112018009439B1 (enExample)
IL (1) IL259199B (enExample)
MX (1) MX383833B (enExample)
NZ (1) NZ742033A (enExample)
PH (1) PH12018501000A1 (enExample)
RU (1) RU2746188C2 (enExample)
SG (1) SG11201803475YA (enExample)
WO (1) WO2017083867A1 (enExample)
ZA (1) ZA201803739B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3651762B1 (en) * 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019079410A1 (en) 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3732163A4 (en) 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
CN110294717B (zh) * 2018-03-21 2021-01-19 湖南加法检测有限公司 农药全组分中2,2-二取代环丁酮杂质及其衍生物、制备方法与应用
CN108658933A (zh) * 2018-07-13 2018-10-16 南京大学 一种二芳基并噻吩型或二芳基硫醚型氘代烷基的制备方法
US11744825B2 (en) * 2018-08-28 2023-09-05 Afasci, Inc. Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds
US12331022B2 (en) 2019-05-02 2025-06-17 Merck Sharp & Dohme Llc Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
CN115776894A (zh) * 2020-04-29 2023-03-10 普拉西斯精密医药公司 T型钙通道调节剂的使用方法
TWI904281B (zh) * 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
CN112574085A (zh) * 2020-12-18 2021-03-30 南通药明康德医药科技有限公司 一种5-氨基-2-氮杂螺[3.4]辛烷-2-羧酸叔丁酯的制备方法
TW202328067A (zh) * 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
CA3243616A1 (en) * 2022-02-03 2023-08-10 Praxis Precision Medicines, Inc. TREATMENT METHODS USING T-TYPE CALCIUM CHANNEL MODULATORS
US20250214932A1 (en) * 2022-04-01 2025-07-03 Praxis Precision Medicines, Inc. T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof
WO2023192687A1 (en) * 2022-04-01 2023-10-05 Praxis Precision Medicines, Inc. T-type calcium channel modulators comprising an azaspiroheptane core and methods of use thereof
CN119300820A (zh) * 2022-04-01 2025-01-10 普拉西斯精密医药公司 包含二氮杂螺庚烷核的t型钙通道调节剂和其使用方法
EP4673131A1 (en) * 2023-03-02 2026-01-07 Praxis Precision Medicines, Inc. High strength single unit dose formulations and methods of use thereof
EP4673132A1 (en) * 2023-03-02 2026-01-07 Praxis Precision Medicines, Inc. Methods of treating essential tremor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047703A2 (en) * 2010-10-04 2012-04-12 Schering Corporation Cyclopropyl-spiro-piperidines useful as sodium channel blockers
US20130065926A1 (en) * 2008-06-02 2013-03-14 Hassan A. Pajouhesh N-piperidinyl acetamide derivatives as calcium channel blockers
EA018195B1 (ru) * 2007-06-15 2013-06-28 Ньюрон Фармасьютикалс С.П.А. Замещенные 2-[2-(фенил)этиламино]алканамидные производные и применение указанных соединений в качестве модуляторов натриевых и/или кальциевых каналов

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
US20100222387A1 (en) 2005-06-23 2010-09-02 Barrow James C 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists
JP2009500340A (ja) * 2005-06-29 2009-01-08 メルク エンド カムパニー インコーポレーテッド ４−フルオロ−ピペリジンｔ型カルシウムチャネルアンタゴニスト
DE102005030231B4 (de) 2005-06-29 2007-05-31 Forschungszentrum Karlsruhe Gmbh Verfahren zum Aufbringen einer hochtemperaturgeeigneten FeCrAl-Schutzschicht, Hüllrohr mit einer derartig aufgebrachten Schutzschicht und Verwendung eines solchen Hüllrohrs
US20140005174A1 (en) 2011-03-17 2014-01-02 Anilkumar G. Nair Indole derivatives useful as ccr2 antagonists
AU2012311698B2 (en) * 2011-09-22 2017-06-22 Merck Sharp & Dohme B.V. N-piperidin-4-yl derivatives
HRP20170411T1 (hr) * 2012-03-02 2017-06-16 Genentech, Inc. Amido spirocilični amidni i sulfonamidni derivati
KR101556318B1 (ko) * 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
HK1214820A1 (zh) * 2013-07-03 2016-08-05 豪夫迈．罗氏有限公司 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
JP2017001954A (ja) 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018195B1 (ru) * 2007-06-15 2013-06-28 Ньюрон Фармасьютикалс С.П.А. Замещенные 2-[2-(фенил)этиламино]алканамидные производные и применение указанных соединений в качестве модуляторов натриевых и/или кальциевых каналов
US20130065926A1 (en) * 2008-06-02 2013-03-14 Hassan A. Pajouhesh N-piperidinyl acetamide derivatives as calcium channel blockers
WO2012047703A2 (en) * 2010-10-04 2012-04-12 Schering Corporation Cyclopropyl-spiro-piperidines useful as sodium channel blockers

Also Published As

Publication number Publication date
ZA201803739B (en) 2019-04-24
EP3340988A4 (en) 2019-05-15
CN108289886A (zh) 2018-07-17
AU2016353446B2 (en) 2022-05-19
WO2017083867A1 (en) 2017-05-18
PH12018501000A1 (en) 2019-01-28
US20180312471A1 (en) 2018-11-01
CA3004448A1 (en) 2017-05-18
CN108289886B (zh) 2022-01-28
JP2018533593A (ja) 2018-11-15
EP3340988B1 (en) 2025-04-09
EP3340988A1 (en) 2018-07-04
BR112018009439B1 (pt) 2023-12-12
KR102217524B1 (ko) 2021-02-19
KR20180074705A (ko) 2018-07-03
RU2018121288A (ru) 2019-12-16
US10562857B2 (en) 2020-02-18
AU2016353446A1 (en) 2018-05-24
BR112018009439A2 (pt) 2018-12-04
SG11201803475YA (en) 2018-05-30
JP6790094B2 (ja) 2020-11-25
RU2018121288A3 (enExample) 2020-03-27
IL259199A (en) 2018-07-31
NZ742033A (en) 2022-11-25
MX2018005242A (es) 2019-03-18
HK1254407A1 (zh) 2019-07-19
EP3340988C0 (en) 2025-04-09
IL259199B (en) 2022-03-01
MX383833B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
AU2016353446B2 (en) Ion channel inhibitory compounds, pharmaceutical formulations and uses
KR101839137B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR102479789B1 (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
JP6683712B2 (ja) ネクローシス阻害薬
IL322853A (en) History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy
KR102204804B1 (ko) 디히드로피라졸 gpr40 조절제
UA114406C2 (uk) Похідні циклопропанаміну як інгібітори lsd1
RU2477721C2 (ru) Замещенные n-фенилпирролидинилметилпирролидинамиды и их терапевтическое применение в качестве модуляторов рецептора н3 гистамина
WO2017109061A1 (en) Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
PH12014501162B1 (en) Aryl dihydropyridinone and piperidinone as mgat2 inhibitors
JP5139307B2 (ja) ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体
JP2024517678A (ja) ソルチリン活性の修飾物質
KR102804113B1 (ko) 알킬 다이하이드로퀴놀린 설폰아마이드 화합물
KR20160120790A (ko) 대사 장애의 치료에 사용하기 위한 디히드로피리디논 mgat2 억제제
AU2019247842B2 (en) Opioid receptor modulators and products and methods related thereto
CA2412164C (en) Amidine derivatives as selective antagonists of nmda receptors
CA2913913A1 (en) Dihydropyridinone mgat2 inhibitors
TW202233620A (zh) Cftr調節劑化合物、組合物及其用途
CA2985769A1 (en) Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
KR20190099048A (ko) 아미드 화합물 및 그 용도
TWI659022B (zh) 作為d-胺基酸氧化酶(daao)抑制劑之新穎經取代苯并咪唑衍生物
CA3004448C (en) Ion channel inhibitory compounds, pharmaceutical formulations and uses
WO2012046771A1 (ja) シクロアルカン化合物
HK1254407B (en) Ion channel inhibitory compounds, pharmaceutical formulations and uses
JP6500201B2 (ja) 置換トロパン誘導体